Mesoblast secures up to $50M for Ryoncil product, pending FDA approval and launch plans by January 7, 2025.

Mesoblast Limited has secured an agreement with its largest shareholder, Gregory George, to potentially issue up to $50 million in convertible notes, pending FDA approval of its product Ryoncil (remestemcel-L) for treating children with steroid-refractory acute graft versus host disease. The funding will support Mesoblast's commercial strategy. An FDA decision is expected by January 7, 2025, aligning with the company's launch plans.

September 30, 2024
3 Articles

Further Reading